Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation

dc.contributor.author Keilp, John G.
dc.contributor.author Madden, Sean P.
dc.contributor.author Marver, Julia E.
dc.contributor.author Frawley, Abigail
dc.contributor.author Burke, Ainsley K.
dc.contributor.author Herzallah, Mohammad M.
dc.contributor.author Gluck, Mark
dc.contributor.author Mann, J. John
dc.date.accessioned 2021-11-10T08:25:31Z
dc.date.available 2021-11-10T08:25:31Z
dc.date.issued 2021-11-10
dc.description.abstract You are prohibited from making this PDF publicly available.For reprints or permissions, contact permissions@psychiatrist.com. ♦ © 2021 Copyright Physicians Postgraduate Press, Inc.It is illegal to post this copyrighted PDF on any website. e1J Clin Psychiatry 82:6, November/December 2021 Focus on Suicide ABSTRACT Objective: Subanesthetic ketamine rapidly reduces depressive symptoms and suicidal ideation in some depressed patients. Its effects on neurocognitive functioning in such individuals with significant suicidal ideation is not well understood, even though certain neurocognitive deficits are associated with suicide behavior beyond clinical symptoms. Methods: In this study, depressed patients with clinically significant suicidal ideation (n = 78) underwent neuropsychological testing before and 1 day after double-blind treatment with intravenous ketamine (n = 39) or midazolam (n = 39). A subgroup randomized to midazolam whose ideation did not remit after initial infusion received open ketamine and additional neurocognitive testing a day after this treatment. The primary outcome was change in performance on this neurocognitive battery. The study was conducted between November 2012 and January 2017. Results: Blinded ketamine produced rapid improvement in suicidal ideation and mood in comparison to midazolam, as we had reported previously. Ketamine, relative to midazolam, was also associated with specific improvement in reaction time (Choice RT) and interference processing/cognitive control (computerized Stroop task)—the latter a measure that has been associated with past suicide attempt in depression. In midazolam nonremitters later treated with open ketamine and retested, reaction time and interference processing/cognitive control also improved relative to both of their prior assessments. Neurocognitive improvement, however, was not correlated with changes in depression, suicidal thinking, or general mood. Conclusions: Overall, ketamine was found to have a positive therapeutic effect on neurocognition 1 day after treatment on at least 1 measure associated with suicidal behavior in the context of depression. Results suggest additional independent therapeutic effects for ketamine in the treatment of depressed patients at risk for suicidal behavior. en_US
dc.identifier.issn 1555-2101
dc.identifier.uri https://dspace.alquds.edu/handle/20.500.12213/6491
dc.language.iso en en_US
dc.publisher Physicians Postgraduate Press, Inc. en_US
dc.title Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation en_US
dc.type Article en_US
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
26 Keilp et al., 2021, JCP, Effects of Ketamine Versus Midazolam on Neurocognition at 24 Hours in Depressed Patients With Suicidal Ideation-2.pdf
269.53 KB
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
1.61 KB
Item-specific license agreed upon to submission